Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW.

Lancet. 2011 Jan 1;377(9759):31-41. doi: 10.1016/S0140-6736(10)62110-1. Epub 2010 Dec 6.


Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.

Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z.

Lancet. 2012 Apr 28;379(9826):1591-601. doi: 10.1016/S0140-6736(12)60209-8. Epub 2012 Mar 21.


Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW.

Lancet. 2010 Nov 20;376(9754):1741-50. doi: 10.1016/S0140-6736(10)61543-7. Epub 2010 Oct 21.


Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW.

Lancet. 2012 Apr 28;379(9826):1602-12. doi: 10.1016/S0140-6736(11)61720-0. Epub 2012 Mar 21. Review.


Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.

Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial.

Lancet. 2007 May 12;369(9573):1603-13. Review.


Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.

Algra AM, Rothwell PM.

Lancet Oncol. 2012 May;13(5):518-27. doi: 10.1016/S1470-2045(12)70112-2. Epub 2012 Mar 21. Review.


Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.

Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, Grove A, Gurung B, Morrow S, Clarke A.

Health Technol Assess. 2013 Sep;17(43):1-253. doi: 10.3310/hta17430. Review.


Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.

Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE.

Ann Intern Med. 2013 Jul 16;159(2):77-85. doi: 10.7326/0003-4819-159-2-201307160-00002.


Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.

Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z.

Lancet. 2016 Jul 23;388(10042):365-375. doi: 10.1016/S0140-6736(16)30468-8. Epub 2016 May 18.


Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.

De Schryver EL, Algra A, van Gijn J.

Cochrane Database Syst Rev. 2003;(1):CD001820. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD001820.


Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A.

Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1.


Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).

Burn J, Mathers J, Bishop DT.

Recent Results Cancer Res. 2013;191:157-83. doi: 10.1007/978-3-642-30331-9_9. Review.


Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Antithrombotic Trialists' Collaboration.

BMJ. 2002 Jan 12;324(7329):71-86. Erratum in: BMJ 2002 Jan 19;324(7330):141.


Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials.

Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R.

Am J Med. 2012 Jun;125(6):560-7. doi: 10.1016/j.amjmed.2012.01.017. Epub 2012 Apr 17.


Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.

Robertson L, Ghouri MA, Kovacs F.

Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Review.


Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT; CAPP2 Investigators.

Lancet. 2011 Dec 17;378(9809):2081-7. doi: 10.1016/S0140-6736(11)61049-0. Epub 2011 Oct 27.


Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.


Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE.

JAMA. 2005 Jul 6;294(1):47-55.


Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.

van Kruijsdijk RC, Visseren FL, Ridker PM, Dorresteijn JA, Buring JE, van der Graaf Y, Cook NR.

Heart. 2015 Mar;101(5):369-76. doi: 10.1136/heartjnl-2014-306342. Epub 2014 Dec 4.

Supplemental Content

Support Center